Home / 2026 / November / 17

patients medical cannabis safety cbma

By |2026-11-17T00:43:04+00:0017 November 2026|

Medical cannabis safety: welcome step, now include patients | PatientsCann UK® Skip to content News and opinion Patient voice A welcome step for medical cannabis safety. Now let’s bring patients in. The new Cannabis-Based Medicines Association has joined the Medical Cannabis Clinicians Society in writing to England’s Patient Safety Commissioner, responding to her concerns about prescribing with an offer to work together on standards. It is a positive move, and we want it to succeed. The best way to make sure it does is to involve patients from the start. By Mohammad Wasway Managing Director, PatientsCann UK® 16 November 2026 On this page In short What happened Why now Our concern What we are asking for FAQs Independent view PatientsCann UK® is a patient-led Community Interest Company. We are not a member of the Cannabis-Based Medicines Association or the Medical Cannabis Clinicians Society, and we have no commercial link with either. This is not medical or legal advice. In short What is the Cannabis-Based Medicines Association? The Cannabis-Based Medicines Association (CBMA) is a new UK trade association for licensed operators in cannabis-based medicines, launched on 16 November 2026. Its founding members include Curaleaf, Glass Pharms and Wellford, and voting rights are reserved for licensed UK operators. With the Medical Cannabis Clinicians Society, it has written to Professor Henrietta Hughes OBE, England’s Patient Safety Commissioner, following her public comments in October, offering to work on prescribing safeguards and standards of care (CBMA, 2026). What we welcome: industry and clinicians coming together to put patient safety first, build better evidence and raise standards. Our concern: patients and patient-led groups are not yet part of the conversation, and only licensed operators can vote in the association. What we offer: patient insight and experience, to help make new standards work for the people they are meant to protect. The news What happened On 16 November 2026, the Cannabis-Based Medicines Association launched with a commitment to strengthen patient safety, raise industry standards and support the responsible integration of cannabis-based medicines into mainstream healthcare (CBMA, 2026). The association says it is dedicated only to cannabis-based medicines, unlike broader cannabis industry bodies. Its work is built around three priorities: putting patient safety first, strengthening the clinical evidence base through collaboration with clinics, and raising standards across the industry. On the same day, the CBMA joined the Medical Cannabis Clinicians Society (MCCS) in writing to Professor Henrietta Hughes OBE, England’s Patient Safety Commissioner. The letter follows the Commissioner’s recent public comments about regulation and prescribing practices in the sector, and offers constructive engagement on improving prescribing safeguards and standards of care. The two organisations say they will work more closely to encourage responsible practice, support established clinical guidance, and explore greater consistency and transparency across the sector (CBMA, 2026). What we welcome Why this is a welcome step This is a positive step. It builds on the work the Cannabis Industry Council has already led with licensed operators and clinicians to raise standards and develop guidance across the sector, and we are pleased to see operators and clinicians respond to the Patient Safety Commissioner’s concerns constructively, by offering to work with her on the solutions. The Cannabis Industry Council brings businesses, clinicians, advocacy groups and patients together, and PatientsCann UK® is proud to be a member. That mix of voices is what gives its work weight. A trade association for licensed operators has a narrower role, speaking for the companies it represents, which is why patients need to be heard alongside it. The CBMA’s three priorities, putting patient safety first, strengthening the evidence base and raising standards, are ones we share. We have spent years asking for proper checks before prescribing, better follow-up, consistent quality of medicine and real data on what works. The MCCS has already published good practice guidance, and closer work between the two bodies could help make that the norm across every clinic. Patients are the people most affected when prescribing goes wrong, and the people who lose most when it is restricted badly. An industry that takes safety seriously is good news for all of us. The background Why is this happening now? The CBMA and MCCS letter is a response to public comments from the Patient Safety Commissioner in October. She said the growth of private prescribing has outpaced the systems needed to keep patients safe, and that responsibility is spread across too many organisations, leaving gaps in information and oversight (Kirby, 2026). The numbers show how fast things have moved. Almost two million unlicensed cannabis items (1,967,268) were issued on private prescription in England between June 2025 and May 2026. About three quarters of them were flower (Press Association, 2026). Her comments came alongside a coroner’s report into the death of Oliver Robinson, aged 34, from Bury, who had been prescribed medical cannabis privately by Curaleaf Clinic. The coroner found the prescribing decision relied on an outdated GP record. Curaleaf said it complies with regulatory standards and has improved information-sharing with other healthcare teams (Press Association, 2026). His family is calling for “Oliver’s Law” to tighten prescribing rules. This is not about whether these medicines should be available to patients who may benefit from them. Professor Henrietta Hughes OBE, Patient Safety Commissioner for England (Kirby, 2026) If you need to talk. Samaritans are there day and night on 116 123, free to call. If you would rather not speak, text SHOUT to 85258. If you are worried about your mental health and your prescription, your clinic or GP can review it with you. Our concern The missing voice: patients Our one real concern is who is in the conversation. The new association reserves voting rights for licensed UK operators: the companies that grow, supply, prescribe and dispense. The letter to the Commissioner comes from that industry and from clinicians. Patients are at the heart of what it sets out to achieve, but are not yet part of the discussion. That matters, because patients see medical cannabis from a side that

<p>The post patients medical cannabis safety cbma first appeared on PatientsCann UK®.</p>